Enlivex Appoints Andrew Singer to its Board of Directors
Provided By Globe Newswire
Last update: Apr 17, 2023
Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.
Read more at globenewswire.com
